Home | AI powered stock trade ideas | Market Signals | Breaking Out | New Green AI Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

AI Powered Stock Trade Ideas
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart


All Chart Prices as of Previous Day Close

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.

Last Price: 31.03 - Change: 0.01 - Change %: 0.0322
02/23/2024 16:00:00 EST

Royalty Pharma Plc (RPRX)

Industry: Biotechnology

Price Support Resistance

In the past 20 trading days, RPRX has been trading in a range between $30.30 and $27.51 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

RPRX is trading below resistance at $31.38, about 1% to the upside. There is support at $29.68 -4% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.

Upside / Downside Potential

Royalty Pharma Plc (RPRX) entered a Green zone 13 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $48.67, a potential upside of 56.85% from the recent price of 31.03. Our AI powered stock target predictor currently has a target price of $57.24 a potential move of 84%. The stock is trading 19.76% (potential upside) below its 52 week high of $37.16 and 21.5 % (potential downside) above its 52 week low of $25.54 - based on the recent price.

Company Summary

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

RPRX Website


Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Source: Zacks Investment Research
Fri, 16 Feb 2024 16:31:03 -0500
Sentiment: Neutral
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months
SLB expects strong growth in 2024. Alibaba stock is dirt cheap, and the company plans major buybacks over the next few years.
Source: The Motley Fool
Fri, 16 Feb 2024 05:50:00 -0500
Sentiment: Positive
Royalty Pharma PLC (RPRX) Q4 2023 Earnings Call Transcript
Royalty Pharma PLC (RPRX) Q4 2023 Earnings Call Transcript
Source: Seeking Alpha
Thu, 15 Feb 2024 13:39:09 -0500
Sentiment: Neutral
Royalty Pharma Reports Q4 and Full Year 2023 Results
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2023 and introduced full year 2024 guidance for Portfolio Receipts. “Royalty Pharma delivered outstanding results in 2023,” said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. “We reported another year of strong growth in royalty receipts and deployed substantial capital in value-enhancing transactions, including our strongest year ever for synthetic royalty transactions. Furthermore, a number of positive clinical and regulatory milestones strengthened the outlook for our diversified royalty portfolio. Based on the strong fundamental tailwinds underpinning our business, our strong balance sheet and robust deal pipeline, I am confident we are in an excellent position to fund life sciences innovation and deliver attractive, long-term compounding growth.”
Source: GlobeNewsWire
Thu, 15 Feb 2024 07:30:00 -0500
Sentiment: Neutral
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve the quality of life of all human beings.
Source: InvestorPlace
Thu, 08 Feb 2024 09:10:29 -0500
Sentiment: Positive
Instituions Institution %: 71.856
Last QTR Institution change: 1667347

Insiders %: 3.865
Insiders Purchases last QTR: 485388
Insiders Sales last QTR: 2360679
Insiders Net last QTR: -1875291

Analyst Ratings
Target Price: 48.67
Overall Rating: 4.5
Strong Buys (5): 6
Buys (4): 3
Holds (3): 1
Sells (2): 0
Strong Sells (1): 0

52 Week Hi: 37.1552
52 Week Low: 25.5437
Beta: 0.424
50 Day MA: 28.644
200 Day MA: 29.4209

Earnings / Revenue Trends
Qtr Earnings Growth YOY: -0.507
Qtr Revenue Growth YOY: 0.054
Forward PE: 8.7951
Trailing PE: 12.2648

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!


Stock Analyzed Each Night


Easily Upload Track Your Stocks


See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.